Observational studyContemporary clinical trials2023
Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly - eXTension (ASPREE-XT) Observational Study.
Observational study in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Antiplatelet therapy and incident cognitive impairment or dementia-a systematic review and meta-analysis of randomised clinical trials.Age and ageing · 2023Pooled it
- Elevated alpha-1 antitrypsin and C-reactive protein: association on all-cause and cause-specific mortality in older adults.GeroScience · 2026Trial
- Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.Age and ageing · 2026Trial
- Thyroid-Stimulating Hormone Levels and Depression in Older Adults: Cross-Sectional and Longitudinal Analyses in a Community-Dwelling Population.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Trial
- Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial.European heart journal · 2025Trial
- Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults.Journal of the National Cancer Institute · 2025Trial
- Prescription and Non-prescription Medication Pill Burdens and Their Associations with Health-Related Quality of Life in Older Adults: A Cross-Sectional Study.Drugs & aging · 2025Trial
- Effects of statins on kidney function in older adults.Journal of the American Geriatrics Society · 2025Trial
- The risk associated with ultra-processed food intake on depressive symptoms and mental health in older adults: a target trial emulation.BMC medicine · 2025Trial
- Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults.Neurology · 2025Trial
- Antibiotic Use and Subsequent Cognitive Decline and Dementia Risk in Healthy Older Adults.Neurology · 2025Trial
- Serum Transaminases and Older Adults: Distribution and Associations With All-Cause Mortality.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Trial
- Association between cardiovascular-kidney-metabolic syndrome and risks of 14 age-related health outcomes in primary prevention older population.GeroScience · 2026Article
- Long-term SBP time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.American journal of hypertension · 2026Observational
- Associations between metabolic dysfunction-associated steatotic liver disease and physical and mental health-related quality of life in older adults.GeroScience · 2026Article
- The association between ultra-processed food exposure and cognition in older adults.GeroScience · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Depressive Symptoms in Older Adults.International journal of geriatric psychiatry · 2026Article
- Diet quality and depressive symptoms in older adults, assessing the effect modification by genetic predisposition and low-grade inflammation: a target trial emulation.Molecular psychiatry · 2026Article
- Resting heart rate and cognitive function in ageing: Insights from a secondary data analysis.GeroScience · 2026Article
- Perceptions of end-of-life care quality among bereaved closest contacts of community-dwelling older Australians: a cross-sectional survey of the ASPREE cohort.Research square · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundAspirin as a primary preventative in healthy older adults did not prolong disability-free survival in the ASPREE randomized trial. Observational studies following randomized trials allow assessment of benefits and harms which may not appear during the trial. We describe health characteristics, physical function, and aspirin use in the ASPREE-eXTension (ASPREE-XT) observational study cohort.
methodsDescriptive statistics compared health characteristics of those consented to ASPREE-XT at their first post-trial baseline (XT01) to corresponding ASPREE baseline values, and to those not consented. Likelihood of an indication for aspirin was assessed in participants reporting aspirin use at XT01.
results16,317 (93%) of the remaining and eligible 17,546 ASPREE participants were consented into ASPREE-XT; 14,894 completed XT01. Mean participant age had increased from 74.9 to 80.6 years. Overall health and physical function declined from the original ASPREE baseline; more participants were living alone, there was higher prevalence of chronic kidney disease, diabetes, and frailty, grip strength was lower and gait speed slower. Those not consented into ASPREE-XT were slightly older, and had lower cognitive scores and higher prevalence of age-related conditions than those who continued. 1015/11,717 (8.7%) participants without an apparent indication for aspirin reported using aspirin at XT01.
conclusionsThe ASPREE-XT cohort was slightly less healthy at the XT01 visit than at ASPREE trial initiation, and rates of aspirin use without indication were similar to ASPREE baseline. Participants will be followed long-term to investigate aspirin's potential legacy towards dementia and cancer prevention and explore determinants of healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.